These findings underscore the importance of Lp(a) in the pathophysiology of CAVD and suggest potential implications for the development of targeted therapeutic strategies aimed at mitigating the progression of this prevalent heart valve disorder. This evidence concerns the gene LPA and heart valve disorder.